Industry News
Pharmaceutical Industry News
In a sudden leadership shift,…
In a sudden leadership shift, Legend Biotech announced that its CEO, Ying Huang, Ph.D., resigned on Friday, with no permanent replacement yet named.
The Peptide Wild West
Welcome to the new Wild West of peptides.
F.D.A. Panel’s Vote on Peptides Raises Concerns About a Prescribing Boom
The committee endorsed broader use of the peptides in lightly regulated compounding pharmacies that have grown into a multibillion-dollar business.
As outside experts gathered for a…
As outside experts gathered for a second day to discuss adding certain popular-yet-unapproved peptides to the U.S.’ bulk compounding list, the first to go up against a vote did not fare as well as those
With Hopes High for New H.I.V. Prevention Pill, Merck Takes Steps to Ensure Access
Companies in Africa and India will make generic versions of the pill that could cost as little as $5 per person per year. But access to the drug and other new products in much of
With Hopes High for New H.I.V. Prevention Pill, Merck Takes Steps to Ensure Access
Companies in Africa and India will make generic versions of the pill that could cost as little as $5 per person per year. But access to the drug and other new products in much of
The company is targeting Lilly ad…
The company is targeting Lilly ad campaigns that cite what Novo calls “outdated” clinical trials comparing Lilly’s drugs with Ozempic and Wegovy.
With all eyes on Tavneos’…
With all eyes on Tavneos’ seemingly precarious approval status in the U.S., Amgen is advancing plans to defend the ANCA-associated vasculitis (AAV) drug it inherited in its $3.7 billion buyout of ChemoCentryx.
Three years after gaining three…
Three years after gaining three liver disease assets in its $952 million buyout of Albireo, Ipsen is struggling to develop the trio. The company has reported the failure of liver disease drug Bylvay in a
A survey of 36 U.S….
A survey of 36 U.S. gastroenterologists found that significant treatment gaps remain in the growing IBD drug market despite an expanding range of therapies.
Generic drugmakers will face…
Generic drugmakers will face import tariffs in the U.S., President Donald Trump announced this week. Samsung Biologics is pursuing the biggest M&A deal ever for a Korean biopharma company. In an unconventional move, a U.S.
An FDA advisory committee has…
An FDA advisory committee has recommended that four peptide drugs that were previously restricted because of potential safety concerns be restored to the 503A Bulk Drug Substances list, which would remove the limits on how
On an investor call Thursday,…
On an investor call Thursday, Roche Pharmaceuticals CEO Teresa Graham assured analysts that the U.S. branded market has stabilized after a period of contraction, though the explosive growth that Vabysmo enjoyed early in its launch
As the recent reshoring zeal rolls…
As the recent reshoring zeal rolls on in the United States, BeOne Medicines is beefing up its flagship manufacturing and R&D campus in New Jersey to the tune of $300 million.
A Peptide Showdown: F.D.A. Scientists May Clash With R.F.K.’s Agenda
Agency scientists are advising against allowing widespread use of several peptide injections. Robert F. Kennedy Jr., the health secretary, has said people should be free to experiment.
The FDA slammed a pair of…
The FDA slammed a pair of India-based API manufacturers in separate warning letters outlining poor record-keeping, problems maintaining sanitation and licensing issues, among other observations.
The former quarterback spoke with…
The former quarterback spoke with Fierce Pharma Marketing on teaming up with ARS, his journey with food allergies and why needle-free epinephrine Neffy is an "incredible option."
In a landmark moment for its…
In a landmark moment for its oncology ambitions, GSK has secured FDA approval for Jideytro as the first commercial lung cancer drug in the company’s history. The milestone was made possible by GSK’s recent acquisition
Directors Andrew Goldstein and…
Directors Andrew Goldstein and Valerie Bowling discuss what to expect at the 2026 PODD: Partnership Opportunities in Drug Delivery conference.
Trump’s New Trade Fights (and Deals)
President Trump has resumed his approach of big threats against some trading partners and generous pacts with others. Experts see new risks.